Germline Testing Recommendation (GTR) in Non Small Cell Lung Cancer (NSCLC) after Broad Tumor Sequencing: Evaluating the Impact of More/Less Conservative Criteria from ESMO/ASCO
Next-generation sequencing (NGS) has improved the detection of actionable variants in cancer drivers, yet distinguishing between germline and somatic mutations in tumor-only NGS remains challenging. Identifying potential germline variants in non-squamous NSCLC is vital for patient care and familial risk. Notably, in tumor and germline sequencing cohorts, nearly 5% of lung cancer
patients (Tempus Lab, USA) harbor pathogenic germline variants, primarily in DNA damage repair genes.
